What I have: oral semaglutide · bacteriostatic water.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Which parts of this are load-bearing and which parts are habit?
The relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
Stated carefully, additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
Ask for the certificate of analysis on the lot. A serious facility has one.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the jurisdiction, since the framework differs substantially between countries and even between states.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.
A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.
Compounded means unapproved by definition. That is structural, not pejorative.
Salt forms and additives are the usual point of divergence and are worth asking about specifically.
Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
Nothing here is medical advice.
Check the beyond-use date and what it was based on.
edited 26 Oct 2025 by ilaria_bertone — tightened the wording; no substantive change
The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.
Facility quality is the dominant variable and cannot be assessed from a website.
Ask which salt form. A different salt is a different active moiety.
The short version: legitimate under a prescription within defined limits, unapproved by definition, and quality depends entirely on the facility.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
The statutory basis for the 503A/503B distinction is sections 503A and 503B of the US Federal Food, Drug, and Cosmetic Act as amended by the Drug Quality and Security Act of 2013, and the FDA’s guidance documents on each are the authoritative description of what is permitted.
The framework is jurisdiction-specific. Check yours rather than a general answer.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.